CO2022017112A2 - N-cianopirrolidinas con actividad como inhibidores de peptidasa específica de ubiquitina 30 - Google Patents

N-cianopirrolidinas con actividad como inhibidores de peptidasa específica de ubiquitina 30

Info

Publication number
CO2022017112A2
CO2022017112A2 CONC2022/0017112A CO2022017112A CO2022017112A2 CO 2022017112 A2 CO2022017112 A2 CO 2022017112A2 CO 2022017112 A CO2022017112 A CO 2022017112A CO 2022017112 A2 CO2022017112 A2 CO 2022017112A2
Authority
CO
Colombia
Prior art keywords
cyanopyrrolidines
activity
ubiquitin
specific peptidase
peptidase inhibitors
Prior art date
Application number
CONC2022/0017112A
Other languages
English (en)
Inventor
Paul William Thompson
Christopher Andrew Luckhurst
Mark Ian Kemp
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2008401.8A external-priority patent/GB202008401D0/en
Priority claimed from GBGB2016689.8A external-priority patent/GB202016689D0/en
Priority claimed from GBGB2101935.1A external-priority patent/GB202101935D0/en
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of CO2022017112A2 publication Critical patent/CO2022017112A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a una clase de N-cianopirrolidinas con actividad como inhibidores de la enzima de desubiquitinación USP30, que tiene utilidad en una variedad de áreas terapéuticas, incluyendo condiciones que involucran la disfunción mitocondrial, cáncer y fibrosis: .
CONC2022/0017112A 2020-06-04 2022-11-29 N-cianopirrolidinas con actividad como inhibidores de peptidasa específica de ubiquitina 30 CO2022017112A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2008401.8A GB202008401D0 (en) 2020-06-04 2020-06-04 Novel compounds
GBGB2016689.8A GB202016689D0 (en) 2020-10-21 2020-10-21 Novel compounds
GBGB2101935.1A GB202101935D0 (en) 2021-02-11 2021-02-11 Novel compounds
PCT/EP2021/064897 WO2021245186A1 (en) 2020-06-04 2021-06-03 N-cyanopyrrolidines with activity as usp30 inhibitors

Publications (1)

Publication Number Publication Date
CO2022017112A2 true CO2022017112A2 (es) 2022-12-09

Family

ID=76421953

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0017112A CO2022017112A2 (es) 2020-06-04 2022-11-29 N-cianopirrolidinas con actividad como inhibidores de peptidasa específica de ubiquitina 30

Country Status (12)

Country Link
US (1) US20230303547A1 (es)
EP (1) EP4161920A1 (es)
JP (1) JP2023529570A (es)
KR (1) KR20230019198A (es)
CN (1) CN115698001A (es)
AU (1) AU2021285130A1 (es)
BR (1) BR112022019722A2 (es)
CA (1) CA3185654A1 (es)
CO (1) CO2022017112A2 (es)
IL (1) IL298710A (es)
MX (1) MX2022015254A (es)
WO (1) WO2021245186A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2001077073A1 (en) 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP2010167A2 (en) 2006-04-13 2009-01-07 Actelion Pharmaceuticals Ltd. Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
EP2152079A4 (en) 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
UY31299A1 (es) 2007-08-20 2009-03-31 Nuevos inhibidores de catepsina y su uso
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
UY31771A1 (es) 2008-04-18 2009-09-30 Inhibidores de catepsina c
WO2009129371A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
AU2014296261B2 (en) 2013-07-31 2018-11-15 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof
EP3145505A4 (en) 2014-05-19 2018-02-28 Northeastern University N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof
JP2017516801A (ja) 2014-05-27 2017-06-22 ファーマケア，インク． 脱ユビキチン化酵素阻害剤の組成物と送達の方法
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
SG11201706542TA (en) 2015-03-30 2017-10-30 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
WO2017009650A1 (en) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
JP6959252B2 (ja) 2016-03-24 2021-11-02 ミッション セラピューティクス リミティド Ｄｕｂ阻害剤としての１−シアノピロリジン誘導体
ES2850349T3 (es) 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
US10968172B2 (en) 2017-05-15 2021-04-06 Mitobridge, Inc. USP30 inhibitors
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
GB2563595B (en) 2017-06-19 2020-04-15 Edwards Ltd Twin-shaft pumps
WO2019071073A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN
GB2571731A (en) 2018-03-06 2019-09-11 Mission Therapeutics Ltd Novel compounds and uses
BR112020021921A2 (pt) 2018-05-17 2021-01-26 Forma Therapeutics, Inc. compostos bicíclicos fundidos úteis como inibidores de peptidase 30 específica de ubiquitina
US11572374B2 (en) 2018-08-14 2023-02-07 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
DK3860989T3 (da) 2018-10-05 2023-05-01 Forma Therapeutics Inc Kondenserede pyrroliner der fungerer som inhibitorer af ubiquitin-specifik protease 30 (usp30)
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
CA3185654A1 (en) 2021-12-09
MX2022015254A (es) 2023-01-11
EP4161920A1 (en) 2023-04-12
JP2023529570A (ja) 2023-07-11
BR112022019722A2 (pt) 2022-12-20
WO2021245186A1 (en) 2021-12-09
IL298710A (en) 2023-02-01
KR20230019198A (ko) 2023-02-07
US20230303547A1 (en) 2023-09-28
CN115698001A (zh) 2023-02-03
AU2021285130A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
CO2022003608A2 (es) Cianopirrolidinas sustituidas con actividad como inhibidores de usp30
CO2022014134A2 (es) N-cianopirrolidinas con actividad como inhibidores de usp30
CO2019014682A2 (es) Composiciones y métodos para enzimas de internalización
CO2022017112A2 (es) N-cianopirrolidinas con actividad como inhibidores de peptidasa específica de ubiquitina 30
MX2016006489A (es) Alfa-amilasas variantes que tienen susceptibilidad reducida a la escision por proteasas y metodos de uso.
CR8993A (es) Procesos e intermediarios para preparar inhibidores de cisteina proteasa
PT1178958E (pt) N-cianometilamidas como inibidores de proteases
BR0114917A (pt) Inibidores de pirimidina-2,4,6-triona metaloproteinase
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
ES2572160T3 (es) Una nueva preparación farmacéutica para preeclampsia
CR6026A (es) Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
MX2023000998A (es) Composiciones genomodificadas dirigidas a los musculos.
AR030741A1 (es) Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa
EA201691018A1 (ru) Фармацевтическая композиция, содержащая смесь проферментов и ферментов
MX2016000480A (es) Composiciones farmaceuticas de pancreatina de alta potencia.
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
MX2023002411A (es) Celulas inmunitarias modificadas para fibrosis e inflamacion.
AR125796A1 (es) Compuesto cíclico que tiene una acción inhibitoria selectiva en kras sobre hras y nras
CO2021016775A2 (es) Método de riego que utiliza hidrogeles en el suelo para extraer agua de la atmosfera
WO2019204332A3 (en) Pak4 inhibitors and methods of use
BR112022024794A2 (pt) Hexahidropirrolo[3,4-b]pirrolo-5(1h)-carbonitrilas com atividade como inibidores de usp30 para uso no tratamento de disfunção mitocondrial, câncer e fibrose
PE20121537A1 (es) Combinacion de teobromina con un descongestivo
MX2021001361A (es) Composicion liquida de fibrinogeno humano.
ITMI20022118A1 (it) Procedimento per la coltura su larga scala di t-linfociti in un sistema omogeneo.